Key Business Highlights - The Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease is expected to begin in Q1-2025, with initial data read-out anticipated around mid-2025 [1][4]. - A new Scientific Advisory Board (SAB) for Obesity, Metabolic & Inflammatory Disease was formed in October 2024 to support the development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications [1][6]. - Two proof-of-concept studies for IC 100 in diet-induced obesity (DIO) mouse models are planned, with at least one study expected to begin in Q4-2024 [1][7]. - An Investigational New Drug (IND) submission for IC 100 is planned for Q2-2025, followed by a Phase 1 clinical trial in healthy overweight subjects at risk for metabolic complications, with safety data expected in H2-2025 [1][5]. Financial Results - For the quarter ended September 30, 2024, the company reported net losses of approximately $2.4 million, an improvement of about $0.5 million or 17.3% compared to a net loss of approximately $2.9 million for the same period in 2023 [7][8]. - Research and development expenses were approximately $0.4 million for the three months ended September 30, 2024, a decrease of about $0.2 million or 35.3% from the same period in 2023 [9]. - General and administrative expenses were approximately $1.8 million for the three months ended September 30, 2024, a decrease of about $0.4 million or 17.7% compared to the same period in 2023 [10]. Cash Position and Funding Needs - As of September 30, 2024, the company had approximately $0.1 million in cash, which is expected to be sufficient for month-to-month operating expenses, but additional financing will be needed to support ongoing operations and clinical activities [8]. - The company plans to seek funding through public or private equity, debt financings, government grants, collaborations, or outstanding warrant exercises [8]. Company Overview - ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases with high unmet medical needs [2][11]. - The company is positioned in the emerging inflammasome space with its lead compounds, Inflammasome ASC Inhibitor IC 100 for obesity and its associated metabolic complications, and Cholesterol Efflux Mediator™ VAR 200 for focal segmental glomerulosclerosis (FSGS) [11]. - The total accessible market for these therapeutic areas is estimated to exceed $100 billion [11].

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UKCash, cash equivalents, other financial assets and marketable securities of $193.8 million DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric ...

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our cutting-edge ...

SAN ANTONIO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ: RXT), a leading hybrid, multicloud, and AI technology services company, announced today that it will work with Amazon Web Services (AWS), an Amazon.com, Inc. company, as part of the company’s new Generative AI Partner Innovation Alliance. The Generative AI Partner Innovation Alliance will help scale and expand the reach of the AWS Generative AI Innovation Center (GenAIIC) - a program that helps AWS customers successfully build and ...

FISHKILL, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced that Van Wyck Mews, an exceptional new home community in Fishkill, New York, has released its final condominiums for sale in the community. This final building of 20 luxury condos in this established community offers quick move-in homes with Designer Appointed Features that will be move-in ready in spring 2025. Pricing for these final homes starts in the mid-$400,00 ...

On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study. These data will be presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to avoid the toxicities associated with the inhibition of FGFR1, FGFR2, and FGFR4 while being agnostic for the FGFR3 ga ...

Fulcrum Therapeutics (FULC) , a clinical-stage company, is expected to report third-quarter 2024 results early next month. The Zacks Consensus Estimate for the to-be-reported quarter's loss is pinned at 40 cents per share. The company currently does not have any marketed products and does not record any revenues. The Zacks Consensus Estimate for Fulcrum's loss per share has narrowed from 46 cents to 28 cents for 2024 over the past 60 days, while that for 2025 has narrowed from $1.51 to $1.14. FULC Estimate ...

Bed Bath & Beyond's owner said in a regulatory filing that it will cut one-fifth of its workforce.Beyond, Inc., formerly known as Overstock, bought the BB&B brand after the original went bankrupt.As an online-only retailer, the company says the cuts will support its "affinity and data monetization model." Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read preview Thanks for signing up! Go to newsletter preferences Thanks for signing up! ...

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell™ technology, designed to create accessible and disease ...

BofA Securities has upgraded Tyra Biosciences TYRA, a clinical-stage biotechnology company focused on developing next-generation precision medicines. The company's initial focus is on improving small molecule drug discovery and development in targeted oncology and genetically defined conditions. The company has a pipeline of four preclinical candidates. In July, Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300 in hypochondroplasia (HCH), the most common form of dwarfism. TYRA-30 ...